OTCMKTS:CTTC

Calmare Therapeutics Stock Forecast, Price & News

$0.13
+0.01 (+8.33 %)
(As of 06/18/2021 12:00 AM ET)
Add
Compare
Today's Range
$0.09
▼
$0.13
50-Day Range
$0.06
▼
$0.20
52-Week Range
$0.03
▼
$0.20
Volume10,000 shs
Average Volume10,033 shs
Market Capitalization$3.95 million
P/E RatioN/A
Dividend YieldN/A
Beta0.68
30 days | 90 days | 365 days | Advanced Chart
Receive CTTC News and Ratings via Email

Sign-up to receive the latest news and ratings for Calmare Therapeutics and its competitors with MarketBeat's FREE daily newsletter.


Calmare Therapeutics logo

About Calmare Therapeutics

Calmare Therapeutics Incorporated, a medical device company, develops and commercializes products and technologies for chronic neuropathic pain and wound care affliction patients in the United States. Its flagship medical device is Calmare Pain Therapy Device, a non-invasive and non-addictive modality for the treatment of chronic and neuropathic pain. The company was formerly known as Competitive Technologies, Inc. and changed its name to Calmare Therapeutics Incorporated in August 2014. Calmare Therapeutics Incorporated was founded in 1968 and is based in Fairfield, Connecticut.

Headlines

Calmare Therapeutics (OTCMKTS:CTTC) Stock Crosses Above 50 Day Moving Average of $0.11
Calmare Therapeutics (OTCMKTS:CTTC) Stock Crosses Above 50 Day Moving Average of $0.11
June 3, 2021 |  americanbankingnews.com
Calmare Therapeutics (OTCMKTS:CTTC) Share Price Crosses Below 50 Day Moving Average of $0.12
Calmare Therapeutics (OTCMKTS:CTTC) Share Price Crosses Below 50 Day Moving Average of $0.12
May 26, 2021 |  americanbankingnews.com
News for Calmare Therapeutics Inc
News for Calmare Therapeutics Inc
December 24, 2020 |  markets.businessinsider.com
Calmare Therapeutics Inc
Calmare Therapeutics Inc
November 15, 2020 |  bloomberg.com
Calmare Therapeutics Incorporated (CTTC)
Calmare Therapeutics Incorporated (CTTC)
October 24, 2020 |  finance.yahoo.com
Calmare Therapeutics Incorporated: Insurance Carrier Denial of Coverage for Calmare Pain Mitigation Therapy Overturned in California
Calmare Therapeutics Incorporated: Insurance Carrier Denial of Coverage for Calmare Pain Mitigation Therapy Overturned in California
August 3, 2020 |  finanznachrichten.de
Insurance Carrier Denial of Coverage for Calmare Pain Mitigation Therapy(TM) Overturned in California
Insurance Carrier Denial of Coverage for Calmare Pain Mitigation Therapy(TM) Overturned in California
August 3, 2020 |  finance.yahoo.com
Calmare Therapeutics Awarded $2.5 Million, Five-Year Contract by U.S. Department of Veteran Affairs for Calmare(R) Pain Therapy Devices
Calmare Therapeutics Awarded $2.5 Million, Five-Year Contract by U.S. Department of Veteran Affairs for Calmare(R) Pain Therapy Devices
June 9, 2020 |  finance.yahoo.com
Calmare Therapeutics Incorporated: Calmare Therapeutics CEO Issues Statement
Calmare Therapeutics Incorporated: Calmare Therapeutics CEO Issues Statement
March 16, 2020 |  www.finanznachrichten.de
Calmare Therapeutics CEO Issues Statement
Calmare Therapeutics CEO Issues Statement
March 16, 2020 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank™

Overall MarketRank™

0.38 out of 5 stars

Medical Sector

1823rd out of 2,100 stocks

Surgical & Medical Instruments Industry

153rd out of 174 stocks

Analyst Opinion: 0.0Community Rank: 1.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Calmare Therapeutics (OTCMKTS:CTTC) Frequently Asked Questions

What stocks does MarketBeat like better than Calmare Therapeutics?

Wall Street analysts have given Calmare Therapeutics a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Calmare Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

How has Calmare Therapeutics' stock price been impacted by COVID-19?

Calmare Therapeutics' stock was trading at $0.0995 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, CTTC stock has increased by 30.7% and is now trading at $0.13.
View which stocks have been most impacted by COVID-19.

Who are Calmare Therapeutics' key executives?

Calmare Therapeutics' management team includes the following people:
  • Mr. Conrad F. Mir, Pres, CEO & Director (Age 52, Pay $279k)
  • Mr. Thomas Philip Richtarich M.B.A., Chief Financial Officer (Age 68, Pay $113.02k)
  • Ms. Donna J. Mays, Mang. of Admin. Services
  • Dr. Stephen J. D'Amato, Chief Medical Officer & Member of Medical Advisory Board (Age 73)
  • Mr. William Lipford, Division Head of Product Sales

Who are some of Calmare Therapeutics' key competitors?

Some companies that are related to Calmare Therapeutics include NeuroMetrix (NURO), Encision (ECIA), Biostage (BSTG), MeaTech 3D (MTTCF), Cellect Biotechnology (APOP), H-CYTE (HCYT), Regenicin (RGIN), Safeplus International (BIPHD), Safeplus International (ACAI), CVR Medical (CRRVF), Hypertension Diagnostics (HDII), Medite Cancer Diagnostics (MDIT), United American Healthcare (UAHC), EKIMAS (ASNB) and Endologix (ELGXQ).
View all of CTTC's competitors.

What other stocks do shareholders of Calmare Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Calmare Therapeutics investors own include Idera Pharmaceuticals (IDRA), Brainstorm Cell Therapeutics (BCLI), Costco Wholesale (COST), Blue Apron (APRN), (APHA), Arista Networks (ANET), Amgen (AMGN), Advanced Micro Devices (AMD), Akers Biosciences (AKER) and AdvisorShares Vice ETF (ACT).

What is Calmare Therapeutics' stock symbol?

Calmare Therapeutics trades on the OTCMKTS under the ticker symbol "CTTC."

How do I buy shares of Calmare Therapeutics?

Shares of CTTC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Calmare Therapeutics' stock price today?

One share of CTTC stock can currently be purchased for approximately $0.13.

How much money does Calmare Therapeutics make?

Calmare Therapeutics has a market capitalization of $3.95 million.

How many employees does Calmare Therapeutics have?

Calmare Therapeutics employs 7 workers across the globe.

What is Calmare Therapeutics' official website?

The official website for Calmare Therapeutics is www.calmaretherapeutics.com.

Where are Calmare Therapeutics' headquarters?

Calmare Therapeutics is headquartered at 1375 KINGS HIGHWAY EAST SUITE 400, FAIRFIELD CT, 06824.

How can I contact Calmare Therapeutics?

Calmare Therapeutics' mailing address is 1375 KINGS HIGHWAY EAST SUITE 400, FAIRFIELD CT, 06824. The company can be reached via phone at (203) 368-6044 or via email at [email protected]


This page was last updated on 6/18/2021 by MarketBeat.com Staff

As Featured By:

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.